End-to-End CDMO Forge Biologics offers end-to-end gene therapy manufacturing, including AAV development and cGMP production, with integration under the Ajinomoto Bio-Pharma Services umbrella. This positions Forge to attract high-value late-stage programs from biotech startups and larger developers seeking scalable, compliant production and regulatory support.

Strategic Collaborations Recent and ongoing partnerships with Skylark Bio, Epicrispr Biotechnologies, Ascidian Therapeutics, Avista Therapeutics, and collaborations with research foundations illustrate a robust BD footprint. This creates opportunities to engage early-stage gene therapy programs needing manufacturing and process development, plus multi-program collaboration packages.

Platform & Regulatory Forge emphasizes process development, cGMP manufacturing, FUEL platform technologies, and regulatory consultation, enabling cross-sell of development and regulatory services to customers moving from bench to clinic, including retina and systemic programs.

Financial Strength With solid revenue scale and meaningful funding, Forge is positioned to pursue long-term partnerships and capacity commitments across multiple gene therapy programs, supported by the Ajinomoto network.

Competitive Positioning The company differentiates through a patient-first ethos, strong manufacturing capabilities, and an integrated ecosystem via the Ajinomoto group, offering a compelling value proposition to developers seeking collaborative, scalable gene therapy manufacturing.